Menstrual Cycle · Premenstrual Disorders
RRM Academy Synopsis
PMDD may arise from impaired brain response to allopregnanolone
A 2020 narrative review argues PMDD may arise when brain GABA-A receptors fail to adapt to monthly allopregnanolone shifts. It draws on rodent tests, small human studies and drug trials. In cited studies, peripheral ovarian hormone levels did not separate women with PMDD from other women. Human receptor data are sparse and stress findings are mixed.
Key Findings
- Peripheral ovarian hormone levels, including allopregnanolone, did not separate women with PMDD from asymptomatic women.
- Rats whose progesterone fell fast showed more anxiety-like behavior than rats whose progesterone fell slowly. In a mouse model, withdrawing allopregnanolone raised GABA-A receptor α4 subunit expression, alongside anxiety-like behavior.
- Women with PMDD did not become sedated by allopregnanolone in the luteal phase and paradoxically became sedated in the follicular phase.
- In controls, progesterone waned gradually over the eight days before menses. In women with premenstrual symptoms it stayed stable until three days before menses, then dropped sharply.
- In an initial placebo-controlled trial, luteal-phase sepranolone cut PMDD mood symptom scores by 75%. Physical symptoms did not improve significantly in that trial.
Interpretation
The paper is a narrative review that summarizes rodent, human and drug studies and reports no pooled analysis. Much of the receptor evidence comes from rodents, and the authors describe the human data as sparse. The literature supports the receptor hypothesis without proving it. Findings on the stress hormone axis in PMDD are mixed. The authors suggest SSRIs may act partly through allopregnanolone and say double-blind trials are needed. Sepranolone was in Phase II trials when the review was written, and the authors say larger trials are needed.
RRM Context
Allopregnanolone is made from progesterone. The corpus luteum secretes progesterone after ovulation. Restorative reproductive medicine treats the ovulatory cycle as a vital sign. A mood disorder that follows the luteal phase fits inside that frame. In the cited studies, peripheral hormone levels looked similar in PMDD. The open question is how the brain responds to hormone change. The review covers mechanism and drug studies. Cycle charting and restorative protocols fall outside it.
Abstract
Premenstrual dysphoric disorder (PMDD) is a severe mood disorder with core symptoms (affective lability, irritability, depressed mood, anxiety) and increased sensitivity to stress occurring in the luteal phase of the menstrual cycle. PMDD can be conceptualized as a disorder of suboptimal sensitivity to neuroactive steroid hormones (NASs). In this review, we describe the role of the NAS allopregnanolone (ALLO), a positive allosteric modulator of the GABAA receptor (GABAA-R), in PMDD's pathophysiology. We review evidence of impaired interaction between ALLO and GABAA-Rs in terms of affective symptom expression, with evidence from rodent and human studies. We discuss evidence of increased luteal phase stress sensitivity as a result of poor ALLO-GABA control of the HPA axis. Finally, we describe how treatments such as selective serotonin reuptake inhibitors (SSRIs) and new drugs targeting GABAA-Rs provide evidence for impaired ALLO-GABA function in PMDD. In sum, the literature supports the hypothesis that PMDD pathophysiology is rooted in impaired GABAA-R response to dynamic ALLO fluctuations across the menstrual cycle, manifesting in affective symptoms and poor regulation of physiologic stress response.
Topics
Keywords
Allopregnanolone, Menstrual cycle, Premenstrual dysphoric disorder, Premenstrual syndrome, Progesterone, Women's health
